Between: Mon to Fri: 9 AM to 6 PM IST
Sat: 9 AM to 1 PM IST
| CAGR since inception | |
|---|---|
Market capitalization
Sector allocation
| Name | % of Net Assets |
|---|---|
| SUVEN PHARMACEUTICALS LIMITED | 10.25% |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | 10.13% |
| CIPLA LIMITED | 8.54% |
| IPCA LABORATORIES LIMITED | 7.37% |
| GLOBUS MEDICAL INC | 6.39% |
| See detailed equity holdings » | |
Credit rating profile
Instrument break-up
| Name | % of Net Assets |
|---|---|
| TREPS / REVERSE REPO INVESTMENTS | 1.9% |
| See detailed debt holdings » | |
Chirag has a total work experience of Over 20 years. He joined DSP Mutual Fund in November 2020 as Vice President in Equity Team.
Chirag has also worked with HDFC AMC Limited, Aviva life Insurance, ICICI Securities, Infinity.com Financial Services Limited, Global Markets - Deutsche Equities India Private Limited, Citigroup Global Markets India Private Limited and ICICI Securities. He is a Chartered Accountant (ICAI India) and also holds a Bachelor of Commerce Degree.
| Sr. No. | Scheme Name | Managing since | Period | |||||
|---|---|---|---|---|---|---|---|---|
| 1 Year | 3 Years | 5 Years | ||||||
|
Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement Different plans shall have a different expense structure. The performance details provided herein are of regular plan. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments |
||||||||
| Name | % of Net Assets | SUVEN PHARMACEUTICALS LIMITED | 10.25% | SUN PHARMACEUTICAL INDUSTRIES LIMITED | 10.13% | CIPLA LIMITED | 8.54% | IPCA LABORATORIES LIMITED | 7.37% | GLAND PHARMA LIMITED | 4.84% | LAURUS LABS LIMITED | 3.96% | SAI LIFE SCIENCES LIMITED | 3.73% | ALEMBIC PHARMACEUTICALS LIMITED | 3.59% | PFIZER LIMITED | 2.75% | PROCTER & GAMBLE HEALTH LIMITED | 2.71% | CONCORD BIOTECH LIMITED | 2.48% | INDOCO REMEDIES LIMITED | 2.15% | UNICHEM LABORATORIES LIMITED | 1.73% | ABBOTT LABORATORIES | 1.29% | EMCURE PHARMACEUTICALS LIMITED | 1.14% | AARTI DRUGS LIMITED | 1.01% | ALKEM LABORATORIES LIMITED | 0.59% | LUPIN LIMITED | 0.52% |
|---|
| Name | % of Net Assets | ILLUMINA INC | 4.22% | APOLLO HOSPITALS ENTERPRISE LIMITED | 4% | VIJAYA DIAGNOSTIC CENTRE LIMITED | 3.16% | KOVAI MEDICAL CENTER AND HOSPITAL LIMITED | 3.01% | NARAYANA HRUDAYALAYA LTD. | 1.57% | THYROCARE TECHNOLOGIES LIMITED | 0.53% | JUPITER LIFE LINE HOSPITALS LIMITED | 0.47% | GRAIL INC | 0.1% |
|---|
| Name | % of Net Assets | GLOBUS MEDICAL INC | 6.39% | INTUITIVE SURGICAL INC | 3.19% | LAXMI DENTAL LIMITED | 0.32% |
|---|
| Name | % of Net Assets | ICICI LOMBARD GENERAL INSURANCE COMPANY LIMITED | 1.38% |
|---|
| Name | % of Net Assets | GLOBAL X FUNDS - GLOBAL X GENOMICS & BIOTECHNOLOGY ETF | 0.67% |
|---|
| Name | % of Net Assets | MEDPLUS HEALTH SERVICES LIMITED | 0.47% |
|---|
| Name | Rating | % of Net Assets |
|---|---|---|
| TREPS / REVERSE REPO INVESTMENTS | -- | 1.9% |
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
There is no assurance that the investment objective of the Scheme will be realized